Ability of the new AT1 receptor blocker azilsartan to block angiotensin II-induced AT1 receptor activation after wash-out

Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan

(2012) Shin-ichiro Miura et al.   HYPERTENSION RESEARCH

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I–II essential hypertension: a randomized, double-blind clinical study

(2012) Hiromi Rakugi et al.   HYPERTENSION RESEARCH

Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models

(2011) Keiji Kusumoto et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension

(2011) William B. White et al.   HYPERTENSION

Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring

(2011) Domenic Sica et al.   Journal of Clinical Hypertension

The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure

(2011) George L. Bakris et al.   Journal of Clinical Hypertension

Molecular and cellular effects of azilsartan

(2011) Takashi Kajiya et al.   JOURNAL OF HYPERTENSION

Abilities of candesartan and other AT1 receptor blockers to impair angiotensin II-induced AT1 receptor activation after wash-out

(2011) Yoshihiro Kiya et al.   JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effects

(2010) Masahiro Fujino et al.   HYPERTENSION RESEARCH

In Vitro Antagonistic Properties of a New Angiotensin Type 1 Receptor Blocker, Azilsartan, in Receptor Binding and Function Studies

(2010) M. Ojima et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Review: Angiotensin II type 1 receptor blockers: class effects versus molecular effects

(2010) Shin-ichiro Miura et al.   JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM